A set of experiments at Stanford reveals that suppressing a protein called ataxin 2 dramatically extends survival and improves motor function in a mouse model of ALS.
April 12, 2017 - By Jennie Dusheck
A study led by researchers at Stanford University School of Medicine has revealed a possible new therapeutic approach for amyotrophic lateral sclerosis, a progressive neurodegenerative disease.
The Stanford-led team performed a series of experiments showing that suppressing a certain protein in a mouse model of ALS, or Lou Gehrig’s disease, could markedly extend the animal’s life span. In one experiment, none of the untreated mice lived longer than 29 days, while some of the treated mice lived over 400 days.
A paper describing the work was published online April 12 in Nature. The paper — by senior author Aaron Gitler, PhD, associate professor of genetics, and lead author Lindsay Becker, a graduate student — details a series of experiments that together suggest a possible strategy for treating ALS.
Finding a different approach
ALS is a disease in which the nerve cells in the brain and spinal cord degenerate, leading to wasting of the muscles. Patients gradually lose the ability to move, speak, eat or breathe, often leading to paralysis and death within two to five years.
ALS is inherited in an estimated 5-10 percent of cases. In the remaining cases, the cause is unknown.
One indicator of ALS, as well as other neurodegenerative diseases, is clumps of protein in the brain. In ALS, these clumps, or aggregates, are made up of a protein called TDP-43. Eliminating TDP-43, and therefore the TDP-43 aggregates, might seem like a good way to prevent or cure ALS. But cells need TDP-43 to survive, so suppressing TDP-43 itself is not a good idea.
Some of the mice lived hundreds and hundreds of days.
A different approach was needed. The researchers knew that a second protein, ataxin 2, helped cells survive when TDP-43 formed toxic clumps. Unlike TDP-43, ataxin 2 is not essential for a cell’s survival, making it a reasonable therapeutic target, Gitler said.
In a previous study, the Stanford-led team had shown that when ataxin 2 is suppressed or blocked in yeast cultures and fruit flies that carry the human TDP-43 gene, cells are more resistant to the potential toxic effects of the clumping TDP-43 protein.
In still another study, Gitler and his colleagues had shown that versions of the human ataxin 2 gene that resulted in a more stable ataxin 2 protein — and therefore more of the protein — increased the risk for developing ALS. The researchers reasoned that if mutations that increased the amount of ataxin 2 raised the risk of ALS, maybe lowering the amount of ataxin 2 would protect a person from ALS.
Becker used genetically engineered mice whose neurons produced human TDP-43 protein at high levels. These mice exhibit some features that resemble human ALS, including a buildup of clumps of TDP-43 in their neurons. These mice also have difficulty walking and typically have life spans of no more than 30 days.
“We wanted to find out if we could protect these mice from the consequences of TDP-43 by lowering the amount of ataxin 2,” said Gitler. Becker genetically engineered these ALS mice to have half the normal amount of ataxin 2, and also engineered other mice to completely lack the protein. She found that with half the ataxin 2, the ALS-like mice survived much longer. “But what was really astounding,” said Becker, “was that when we completely removed ataxin 2, there was really an unprecedented survival; some of the mice lived hundreds and hundreds of days.”
A preventive that worked in mice
Gitler’s team next tried something that could have a more direct therapeutic value: treating mice with a type of DNA-like drug, designed to block the production of ataxin 2. These so called “antisense oligonucleotides” are strands of synthetic DNA that target a gene and block the expression of the protein that it encodes. Delivery of the antisense oligonucleotides to the nervous systems of some of the ALS mice enabled them to maintain their health much longer than the ALS mice treated with a placebo.
A similar antisense oligonucleotide was recently approved for safety trials in pediatric patients with spinal muscular atrophy, and other antisense oligonucleotides have passed safety trials — factors that Gitler said give him hope for a similar strategy for ALS.
Becker said the study showed that suppressing ataxin 2 delayed onset and slowed the progression of the ALS-like disease in mice that were not yet showing symptoms. Whether oligonucleotides or other protein-blocking treatments could reverse symptoms in mice that are already sick is another question. “That’s the next set of experiments that we are working on,” she said. Because TDP-43 clumping occurs in nearly all ALS cases, targeting ataxin 2 could be a broadly effective therapeutic strategy, she said.
Other Stanford-affiliated co-authors are postdoctoral scholar Brenda Huang, PhD; graduate student Gregor Bieri; research assistant Rosanna Ma; and postdoctoral scholar David Knowles, PhD.
The research was supported by the National Institutes of Health (grants R01NS065317, R01NS09386501, R01NS073660, R35NS097263 and NS069375), the National Science Foundation, the Robert Packard Center for ALS Research at Johns Hopkins, Target ALS, the Glenn Foundation and the German Research Foundation.
Stanford’s Department of Genetics also supported the work.
About Stanford Medicine
Stanford Medicine is an integrated academic health system comprising the Stanford School of Medicine and adult and pediatric health care delivery systems. Together, they harness the full potential of biomedicine through collaborative research, education and clinical care for patients. For more information, please visit med.stanford.edu.